Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BELLUS Health Inc. stock logo
BLU
BELLUS Health
$14.74
$14.62
$6.38
$14.76
$1.87B0.193.08 million shs3.45 million shs
23andMe Holding Co. stock logo
ME
23andMe
$0.50
-35.3%
$0.81
$0.53
$12.76
$13.36M1.191.27 million shs29.28 million shs
Cassava Sciences, Inc. stock logo
SAVA
Cassava Sciences
$1.83
+3.4%
$1.82
$1.15
$42.20
$88.40M-2.312.96 million shs1.05 million shs
Taro Pharmaceutical Industries Ltd. stock logo
TARO
Taro Pharmaceutical Industries
$42.97
$42.83
$32.67
$45.76
$1.62B0.5645,199 shsN/A
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for May 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BELLUS Health Inc. stock logo
BLU
BELLUS Health
0.00%0.00%0.00%0.00%0.00%
23andMe Holding Co. stock logo
ME
23andMe
0.00%0.00%0.00%-80.08%-94.99%
Cassava Sciences, Inc. stock logo
SAVA
Cassava Sciences
+3.39%+14.38%+44.09%-20.78%-90.95%
Taro Pharmaceutical Industries Ltd. stock logo
TARO
Taro Pharmaceutical Industries
0.00%0.00%0.00%0.00%+1.58%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
BELLUS Health Inc. stock logo
BLU
BELLUS Health
N/AN/AN/AN/AN/AN/AN/AN/A
23andMe Holding Co. stock logo
ME
23andMe
N/AN/AN/AN/AN/AN/AN/AN/A
Cassava Sciences, Inc. stock logo
SAVA
Cassava Sciences
3.6652 of 5 stars
3.32.00.04.71.60.01.3
Taro Pharmaceutical Industries Ltd. stock logo
TARO
Taro Pharmaceutical Industries
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
BELLUS Health Inc. stock logo
BLU
BELLUS Health
0.00
N/AN/AN/A
23andMe Holding Co. stock logo
ME
23andMe
1.00
SellN/AN/A
Cassava Sciences, Inc. stock logo
SAVA
Cassava Sciences
2.50
Moderate Buy$54.502,878.14% Upside
Taro Pharmaceutical Industries Ltd. stock logo
TARO
Taro Pharmaceutical Industries
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest SAVA, TARO, BLU, and ME Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
3/25/2025
Cassava Sciences, Inc. stock logo
SAVA
Cassava Sciences
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral$2.00 ➝ $2.00
3/22/2025
23andMe Holding Co. stock logo
ME
23andMe
Weiss Ratings
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSell (E+) ➝ Sell (E+)
3/7/2025
23andMe Holding Co. stock logo
ME
23andMe
Weiss Ratings
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSell (E+) ➝ Sell (E+)
3/4/2025
Cassava Sciences, Inc. stock logo
SAVA
Cassava Sciences
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral
2/19/2025
23andMe Holding Co. stock logo
ME
23andMe
Weiss Ratings
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSell (E+) ➝ Sell (E+)
(Data available from 5/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
BELLUS Health Inc. stock logo
BLU
BELLUS Health
$15K124,613.93N/AN/A$3.09 per share4.77
23andMe Holding Co. stock logo
ME
23andMe
$208.78M0.06$0.54 per share0.93$2.34 per share0.21
Cassava Sciences, Inc. stock logo
SAVA
Cassava Sciences
N/AN/AN/AN/A$3.26 per shareN/A
Taro Pharmaceutical Industries Ltd. stock logo
TARO
Taro Pharmaceutical Industries
$629.18M2.57$2.38 per share18.03$47.70 per share0.90
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
BELLUS Health Inc. stock logo
BLU
BELLUS Health
-$76.08M-$0.72N/AN/AN/A-578,586.63%-24.27%-23.14%N/A
23andMe Holding Co. stock logo
ME
23andMe
-$666.70M-$15.45N/AN/A-183.39%-170.07%-62.13%N/A
Cassava Sciences, Inc. stock logo
SAVA
Cassava Sciences
-$97.22M-$1.45N/AN/AN/AN/A-88.05%-64.98%N/A
Taro Pharmaceutical Industries Ltd. stock logo
TARO
Taro Pharmaceutical Industries
$53.87M$1.4429.84N/A8.56%3.75%3.09%N/A

Latest SAVA, TARO, BLU, and ME Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/8/2025Q1 2025
Cassava Sciences, Inc. stock logo
SAVA
Cassava Sciences
N/A-$0.48N/A-$0.48N/AN/A
3/3/2025Q4 2024
Cassava Sciences, Inc. stock logo
SAVA
Cassava Sciences
-$0.68-$0.57+$0.11-$0.57N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
BELLUS Health Inc. stock logo
BLU
BELLUS Health
N/AN/AN/AN/AN/A
23andMe Holding Co. stock logo
ME
23andMe
N/AN/AN/AN/AN/A
Cassava Sciences, Inc. stock logo
SAVA
Cassava Sciences
N/AN/AN/AN/AN/A
Taro Pharmaceutical Industries Ltd. stock logo
TARO
Taro Pharmaceutical Industries
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
BELLUS Health Inc. stock logo
BLU
BELLUS Health
N/A
33.42
33.42
23andMe Holding Co. stock logo
ME
23andMe
N/A
1.05
0.91
Cassava Sciences, Inc. stock logo
SAVA
Cassava Sciences
N/A
3.55
3.55
Taro Pharmaceutical Industries Ltd. stock logo
TARO
Taro Pharmaceutical Industries
N/A
3.61
3.04

Institutional Ownership

CompanyInstitutional Ownership
BELLUS Health Inc. stock logo
BLU
BELLUS Health
90.37%
23andMe Holding Co. stock logo
ME
23andMe
36.10%
Cassava Sciences, Inc. stock logo
SAVA
Cassava Sciences
38.05%
Taro Pharmaceutical Industries Ltd. stock logo
TARO
Taro Pharmaceutical Industries
91.40%

Insider Ownership

CompanyInsider Ownership
BELLUS Health Inc. stock logo
BLU
BELLUS Health
24.17%
23andMe Holding Co. stock logo
ME
23andMe
26.32%
Cassava Sciences, Inc. stock logo
SAVA
Cassava Sciences
2.40%
Taro Pharmaceutical Industries Ltd. stock logo
TARO
Taro Pharmaceutical Industries
13.80%
CompanyEmployeesShares OutstandingFree FloatOptionable
BELLUS Health Inc. stock logo
BLU
BELLUS Health
74126.81 million96.16 millionNot Optionable
23andMe Holding Co. stock logo
ME
23andMe
77026.83 million19.77 millionNot Optionable
Cassava Sciences, Inc. stock logo
SAVA
Cassava Sciences
3048.31 million43.78 millionOptionable
Taro Pharmaceutical Industries Ltd. stock logo
TARO
Taro Pharmaceutical Industries
1,55437.59 million32.40 millionOptionable

Recent News About These Companies

Taro to acquire 100% stake in Antibe Therapeutics
Sun Pharma unit poised to buy Canadian biotech Antibe

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
BELLUS Health stock logo

BELLUS Health NASDAQ:BLU

BELLUS Health Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus. BELLUS Health Inc. was incorporated in 1993 and is based in Laval, Canada. As of June 28, 2023, BELLUS Health Inc. operates as a subsidiary of GSK plc.

23andMe stock logo

23andMe NASDAQ:ME

$0.50 -0.27 (-35.32%)
Closing price 03/28/2025
Extended Trading
$0.50 0.00 (0.00%)
As of 03/28/2025 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

23andMe Holding Co. operates as a consumer genetics testing company. The company operates in two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications. This segments also operates Lemonaid telehealth platform to access affiliated licensed healthcare professionals for medical consultation and treatment for various common conditions; and offers research services. The Therapeutics segment focuses on the drug development; and discovery and development of novel therapies to enhance patient lives across various therapeutic areas, including oncology, respiratory, and cardiovascular diseases, as well as offers out-licensing intellectual property associated with identified drug targets related to drug candidates under clinical development. The company's therapeutics product portfolio comprises 23ME-00610 (P006), a humanized monoclonal antibody, which is in phase 1/2a clinical trials to interfere with the ability of CD200R1 to interact with CD200 in cancer cells; and GSK6097608, an antibody that targets CD96 for attenuating T and NK cell anti-tumor immune responses. The company was incorporated in 2006 and is headquartered in South San Francisco, California.

Cassava Sciences stock logo

Cassava Sciences NASDAQ:SAVA

$1.83 +0.06 (+3.39%)
Closing price 05/12/2025 04:00 PM Eastern
Extended Trading
$1.84 +0.01 (+0.82%)
As of 04:12 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.

Taro Pharmaceutical Industries stock logo

Taro Pharmaceutical Industries NYSE:TARO

Taro Pharmaceutical Industries Ltd., a science-based pharmaceutical company, develops, manufactures, and markets prescription and over-the-counter pharmaceutical products in the United States, Canada, Israel, and internationally. The company also develops and manufactures active pharmaceutical ingredients primarily for use in its finished dosage form products. It offers its products for various therapeutic categories comprising allergy, analgesic, antibacterial, antibiotic, anticonvulsant, antiemetic, antifungal, anti-inflammatory, anti-cancer, antiplatelet agent, antipyretic, cardiovascular, CNS, corticosteroid, cosmetic, cough and cold, dermatology, diuretic, endocrine, gastrointestinal, laxative, narcotics, neuropathic pain, neuropsychiatric, sedative/hypnotic, and topical anti-neoplastic. The company provides its products in the form of capsule, cream, drops, emulsion, gel/gel kit, granules, injectable, lotion, oil, ointment, paste, powder/powder for solution, rectal suppository, shampoo, solution/solution for infusion, spray, suspension, syrup, tablets, toothpaste and mouthwash, topical foam, and topical solution. It distributes and sells its products directly to wholesalers, retail drug chains, food chains, hospitals, mass merchandisers, e-commerce stores, and other direct consumers, as well as healthcare institutions and private pharmacies. The company was incorporated in 1959 and is based in Haifa, Israel. Taro Pharmaceutical Industries Ltd. operates as a subsidiary of Alkaloida Chemical Company Zrt. As of June 30, 2023, Taro Pharmaceutical Industries Ltd. operates as a subsidiary of Sun Pharmaceutical Industries Limited.